Magyar onkologia · 2026
[Data and clinical experience of patients undergoing sentinel lymph node biopsy between 2020 and 2025 at the National Institute of Oncology, Hungary].
Аннотация на английскомСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kispál Mihály, Érseki Tamara, Pataki Anna, Diós Emese, Kenessey István, Bőcs Katalin, Papp Eszter, Pánczél Gitta, Ambrus Luca, Czirbesz Kata, Mersich Tamás, Balatoni Tímea
Аннотация
AIM: The authors present a retrospective analysis of sentinel lymph node biopsy (SLNB) data from patients with primary cutaneous melanoma treated at the National Institute of Oncology.
METHODS: A total of 806 patients who underwent SLNB between 2020 and 2025 were included. Primary tumor characteristics were evaluated in relation to progression-free survival (PFS) and overall survival (OS) and, in SLNB-positive patients, the impact of adjuvant therapies was assessed.
RESULTS: Breslow thickness showed a significant negative association with both PFS and OS. Significant differences in survival outcomes were also observed between SLNB-positive and SLNB-negative patients. Among SLNB-positive patients, no significant difference in PFS was detected between those receiving adjuvant therapy and those who did not, nor among different adjuvant modalities. However, adjuvant therapy was associated with a significant improvement in OS.
CONCLUSIONS: Although our findings differ from results reported in clinical trials, longer follow-up is required for proper conclusions.
METHODS: A total of 806 patients who underwent SLNB between 2020 and 2025 were included. Primary tumor characteristics were evaluated in relation to progression-free survival (PFS) and overall survival (OS) and, in SLNB-positive patients, the impact of adjuvant therapies was assessed.
RESULTS: Breslow thickness showed a significant negative association with both PFS and OS. Significant differences in survival outcomes were also observed between SLNB-positive and SLNB-negative patients. Among SLNB-positive patients, no significant difference in PFS was detected between those receiving adjuvant therapy and those who did not, nor among different adjuvant modalities. However, adjuvant therapy was associated with a significant improvement in OS.
CONCLUSIONS: Although our findings differ from results reported in clinical trials, longer follow-up is required for proper conclusions.